MEK-ing the Most of It: Strategies to Co-target Gαq and MAPK in Uveal Melanoma.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 33355300.
- Also identified by DOI 10.1158/1078-0432.CCR-20-4530 and PMC identifier 7925419.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Most uveal melanomas harbor mutations in Gαq and show constitutive MAPK activation. Although MEK inhibition has some efficacy against uveal melanoma, clinical responses are typically poor. The Gαq inhibitor-MEK inhibitor combination showed prolonged suppression of MAPK signaling in preclinical uveal melanoma models and led to improved therapeutic responses.<i>See related article by Hitchman et al., p. 1476</i>.
Medical subject headings
- Melanoma
- Uveal Neoplasms